2021 American Transplant Congress
Short-term Therapy with Anti-icam-1 Monoclonal Antibody Induced Long-term Liver Allograft Survival in Non-human Primates
*Purpose: Tolerance induction remains challenging following liver transplantation and the long-term use of immunosuppressants, especially calcineurin inhibitors, leads to serious complications. We aimed to test…2021 American Transplant Congress
Waitlist Outcomes for Patients with Hepatocellular Carcinoma Following the 2019 Exception Policy Change
*Purpose: We aim to compare waitlist (WL) outcomes for HCC patients after the implementation of the most recent UNOS exception policy change on 5/1/2019.*Methods: All…2021 American Transplant Congress
Should We Worry About Covid-19 Infection in Pediatric SOT?
*Purpose: We describe the clinical presentation & immune response to COVID-19 infection in pediatric SOT.*Methods: Medical records of COVID-19 PCR+ or seropositive patients were reviewed…2021 American Transplant Congress
Hepatitis E Diagnosis and Management After Liver, Kidney, or Heart Transplant: A Single Center Experience
1Wayne State University School of Medicine, Detroit, MI, 2Henry Ford Health System, Detroit, MI
*Purpose: Transplant-related Hepatitis E virus (HEV) infection is a rarely recognized entity with significant clinical importance given potential for chronic hepatitis post-transplant. We evaluated HEV…2021 American Transplant Congress
Dynamics of IgG Subclass as a Mechanism of Desensitization Using Rituximab for Presensitized Patients Undergoing Living Related Liver Transplantation
*Purpose: Although impact of preformed HLA-related donor specific antibody (DSA) and necessity of desensitization in liver transplantation (LT) has been recognized, mechanisms of desensitization in…2021 American Transplant Congress
Intrahepatic Spatial Location of HCC Recurrence Following Loco-regional Therapy for Solitary Tumors Predicts a Higher Oncologic Risk & Increased Recurrence Post-transplant
Columbia University, New York, NY
*Purpose: Loco-Regional therapy (LRT) for hepatocellular carcinoma (HCC) patients is an established bridge to Orthotopic Liver Transplantation (OLT). However, no large cohort data exist correlating…2021 American Transplant Congress
Long-term Outcomes of Donation After Cardiac Death and Living Donor Liver Transplant for Primary Sclerosing Cholangitis: An Analysis of UNOS Registry from 2002-2020
Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI
*Purpose: Use of donation after circulatory death (DCD) grafts is a reported risk factor for worse outcomes after liver transplant (LT) for primary sclerosing cholangitis…2021 American Transplant Congress
Thrombotic and Hemorrhagic Complications Associated with Postoperative Anticoagulation After Pediatric Liver Transplantation
*Purpose: In order to determine the efficacy of post-liver transplant (LT) anticoagulation protocols in reducing the occurrence of arterial thrombosis (HAT) and other vascular complications…2021 American Transplant Congress
A Novel Liver Assist Device as a Bridge to Liver Transplantation in Acute on Chronic Liver Failure Patients with Multi-Organ Failure
*Purpose: Acute on chronic liver failure (AOCLF) occurs in nearly 25% of patients with acutely decompensated cirrhosis, with many developing multi-organ failure requiring ventilatory, vasopressor…2021 American Transplant Congress
Donor-derived Cell-free DNA Distinguishes Acute Rejection from Other Causes of Graft Injury in Liver Transplant Recipients
*Purpose: The donor derived cell-free DNA (ddcfDNA) has emerged as strong biomarker for allograft injury, where the fraction of ddcfDNA is reported to increase in…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 180
- Next Page »